Literature DB >> 4151750

Why do schizophrenic patients refuse to take their drugs?

T Van Putten.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4151750     DOI： 10.1001/archpsyc.1974.01760130049008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN： 0003-990X


× No keyword cloud information.
  60 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  The use of psychotropic drugs in developing countries.

Authors:  T W Harding; T L Chrusciel
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

3.  Adequacy of treatment for serious mental illness in the United States.

Authors:  Philip S Wang; Olga Demler; Ronald C Kessler
Journal:  Am J Public Health       Date:  2002-01       Impact factor: 9.308

Review 4.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

5.  Effects of capitation on health of the chronically ill. Implications for antipsychotic drug therapy.

Authors:  S K Reed; K Maharaj
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

6.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

Review 7.  Lack of insight in schizophrenia: impact on treatment adherence.

Authors:  Peter F Buckley; Donna A Wirshing; Prameet Bhushan; Joseph M Pierre; Seth A Resnick; William C Wirshing
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.

Authors:  Steven M Grauer; Radka Graf; Rachel Navarra; Amy Sung; Sheree F Logue; Gary Stack; Christine Huselton; Zhi Liu; Thomas A Comery; Karen L Marquis; Sharon Rosenzweig-Lipson
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

9.  Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.

Authors:  Pál Czobor; Richard A Van Dorn; Leslie Citrome; Rene S Kahn; W Wolfgang Fleischhacker; Jan Volavka
Journal:  Eur Neuropsychopharmacol       Date:  2015-04-30       Impact factor: 4.600

10.  Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics.

Authors:  L Tune; J T Coyle
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.